Physician profile
Richard E Levine
NPI 1518096692
$3,003.56
in general payments reported to CMS, 2019-2025
23 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $234 · 2021: $766 · 2022: $400 · 2023: $531 · 2024: $337 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $479.81 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $420.26 | 2020-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Abbvie INC. | $295.89 | 2022-2025 | |
| Allergan, INC. | $294.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $265.03 | 2019-2023 | |
| Alcon Vision LLC | $198.47 | 2019-2025 | Clareon, Rocklatan |
| Oyster Point Pharma, INC. | $177.88 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $154.49 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Eyevance Pharmaceuticals LLC | $133.87 | 2019-2022 | |
| Ocular Therapeutix, INC. | $90.55 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.97 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $83.85 | 2019-2021 | |
| Thea Pharma INC. | $71.67 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $67.05 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $32.45 | 2024 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $29.89 | 2019 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Glaukos Corporation | $25.00 | 2024 | Ce-Marked Kxla System |
| Ani Pharmaceuticals, INC. | $17.42 | 2022 | |
| Omeros Corporation | $15.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.82 | 2020 | |
| Rayner Intraocular Lenses Limited | $13.50 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.